FDA approves generic versions of Risperdal for treating schizophrenia

WASHINGTON The Food and Drug Administration has approved two new generic versions of Johnson & Johnson’s Risperdal, the agency’s records show.

The FDA approved Aurobindo Pharma’s version Oct. 8 and Wockhardt’s version Oct. 9.

Several versions of the drug, known generically as risperidone, are already on the market, available from Apotex, Mylan and Teva.